Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Scrapping Its IPO, Phenomix Teams Up With Forest

This article was originally published in The Pink Sheet Daily

Executive Summary

The deal funds ongoing clinical development of dutogliptin and provides a cushion in difficult financial times.

Related Content

Phenomix Folds After Diabetes Drug Fails To Attract Partner To Fill Forest's Shoes
Forest Ends Phenomix Partnership, But Says Its Many Deals Are Bearing Fruit
Deals Of The Week: Pfizer/Protalix, AstraZeneca/Targacept, Chiesi/Phenomix
Phenomix And Chiesi Partner For Phase III DPP-4 Drug In Europe
Forest Snaps Up SNRI, Builds Pipeline
Forest Vows To Double Pipeline Potential
Forest Vows To Double Pipeline Potential
FDA Puts Off Forest’s Fibromyalgia Drug Milnacipran
BMS, AstraZeneca’s Onglyza Enters Murky Regulatory Waters
Takeda Files DPP-4 Inhibitor NDA, Poised To Best Bristol/AstraZeneca, Novartis In Race For Second To Market





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts